Agios Appoints Tsveta Milanova as Chief Commercial Officer
06 December 2022 - 11:00PM
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field
of cellular metabolism pioneering therapies for rare diseases,
today announced the appointment of Tsveta Milanova to the role of
chief commercial officer, effective Jan. 3, 2023. Ms. Milanova will
succeed Richa Poddar, who has been with Agios since 2016 and will
continue to serve as the company’s chief commercial officer until
the end of the year.
“Tsveta brings deep expertise in launching and commercializing
medicines in rare disease and hematology, as well as international
operations and global market access experience that will be a
tremendous asset for Agios as we expand the reach and impact of our
rare disease portfolio and work toward approvals in new indications
and geographies,” said Brian Goff, chief executive officer at
Agios. “Her leadership and strategic insights have contributed to
the exponential growth of leading global biopharmaceutical
companies and have helped to maximize the positive impact of
innovative products for patient communities. I am thrilled she is
joining the Agios team and look forward to her contributions to
shaping our bright future.”
“I am tremendously grateful to Richa for her work at Agios over
the past six years,” continued Mr. Goff. “During her time with the
company, she has displayed remarkable versatility, effectively
taking on roles in corporate strategy and business development,
oncology portfolio management and commercial leadership. She
seamlessly led the transition of the company’s oncology assets
following the divestiture of our oncology business and has been
leading the launch of our first rare disease medicine. She has been
instrumental in helping make Agios what it is today.”
Ms. Milanova joins Agios with two decades of experience in
commercial leadership and global market access in the
biopharmaceutical industry. She spent five years at Alexion in
high-impact commercial and market access roles, including senior
vice president, head of U.S. commercial; senior vice president,
global commercial strategy; and senior vice president, global
value, access and policy. Prior to Alexion, she spent more than ten
years at Celgene in roles of increasing responsibility in global
pricing and market access, most recently as global head, pricing
and market access for the hematology and oncology division. She
holds a master of science (MSc) degree in international health
policy and health economics from the London School of Economics, a
master of science (MSc) degree in pharmacy from the Medical
University of Sofia, Bulgaria and is a graduate of Harvard’s
Advanced Management Program.
“With the approval of its first-in-class PK activator in adults
with pyruvate kinase (PK) deficiency in the U.S. and EU, and the
ongoing pivotal trials of the same medicine in thalassemia,
pediatric PK deficiency and sickle cell disease, Agios has a
special opportunity to make a transformative impact in multiple
rare blood disorders with profound unmet need,” said Ms. Milanova.
“I look forward to working with the Agios team to continue
advancing the PK deficiency launch while building and expanding
commercial capabilities to support potential expansion into
additional indications. PK activation is a promising therapeutic
approach for a number of rare hemolytic and acquired anemias, and I
am excited to work toward improving the lives of people with these
conditions.”
About AgiosAgios is a biopharmaceutical company
that is fueled by connections. The Agios team cultivates strong
bonds with patient communities, healthcare professionals, partners
and colleagues to discover, develop and deliver therapies for rare
diseases. In the U.S., Agios markets a first-in-class pyruvate
kinase (PK) activator for adults with PK deficiency, the first
disease-modifying therapy for this rare, lifelong, debilitating
hemolytic anemia. Building on the company's leadership in the field
of cellular metabolism, Agios is advancing a robust clinical
pipeline of investigational medicines with programs in alpha- and
beta-thalassemia, sickle cell disease, pediatric PK deficiency and
MDS-associated anemia. In addition to its clinical pipeline, Agios
has multiple investigational therapies in preclinical development
and deep scientific expertise in classical hematology. For more
information, please visit the company’s website at
www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the expected benefits of Ms. Milanova’s appointment and
Agios’ strategic plans and focus. The words “anticipate,” “expect,”
“goal,” “hope,” “milestone,” “plan,” “potential,” “possible,”
“strategy,” “will,” “vision,” and similar expressions are intended
to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Agios’ current expectations and beliefs.
Management’s expectations and, therefore, any forward-looking
statements in this press release could also be affected by risks
and uncertainties relating to a number of other important factors,
including, without limitation risks and uncertainties related to:
the impact of the COVID-19 pandemic on Agios’ business, operations,
strategy, goals and anticipated milestones, including its ongoing
and planned research activities, ability to conduct ongoing and
planned clinical trials, clinical supply of current or future drug
candidates, commercial supply of future approved products, and
launching, marketing and selling future approved products; Agios’
results of clinical trials and preclinical studies, including
subsequent analysis of existing data and new data received from
ongoing and future studies; the content and timing of decisions
made by the U.S. FDA, the EMA or other regulatory
authorities, investigational review boards at clinical trial sites
and publication review bodies; Agios’ ability to obtain and
maintain requisite regulatory approvals and to enroll patients in
its planned clinical trials; unplanned cash requirements and
expenditures and competitive factors; Agios’ ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios’
ability to establish and maintain collaborations; the failure of
Agios to receive milestone or royalty payments related to the sale
of its oncology business, the uncertainty of the timing of any
receipt of any such payments, and the uncertainty of the results
and effectiveness of the use of proceeds from the transaction
with Servier; and general economic and market conditions.
These and other risks are described in greater detail under the
caption “Risk Factors” included in Agios’ public filings with
the Securities and Exchange Commission. While the list of
factors presented here is considered representative, this list
should not be considered to be a complete statement of all
potential risks and uncertainties. Any forward-looking statements
contained in this press release are made only as of the date
hereof, and we undertake no obligation to update forward-looking
statements to reflect developments or information obtained after
the date hereof and disclaim any obligation to do so other than as
may be required by law.
Investor & Media Contact:Jessica Rennekamp,
857-209-3286Senior Director, Corporate
CommunicationsJessica.Rennekamp@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024